First findings from the Swiss pilot study point to stable consumption, changing consumption behaviours and the importance of quality, information and professional guidance.
Switzerland’s cannabis pilot projects aim to replace assumptions with evidence.
The first interim results from the SCRIPT study in Bern, Biel and Lucerne now provide another important piece of that evidence. They offer an early view of what happens when adults access cannabis within a controlled, scientifically monitored and professionally supported framework.
More than 1,100 participants have accessed regulated cannabis through pharmacies since 2024. The first findings provide important insights across several areas.
Consumption is not increasing
One of the central questions surrounding regulated access is whether it leads to higher cannabis consumption.
The first SCRIPT results show that this has not been the case. Overall consumption among participants has remained stable, with a slight downward trend.
This finding adds real-world evidence to the broader regulatory discussion. It helps us better understand how legal access affects consumption within a defined and controlled framework.
Professional guidance can influence behaviour
The study also highlights the role of information and professional support.
More participants are choosing potentially lower-risk forms of consumption. These include vaporising and oral use instead of smoking.
The information provided through the study also reaches beyond the participants themselves. 71% report sharing harm-reduction information from SCRIPT with people in their personal networks.
This suggests that a regulated model can create an environment where knowledge travels beyond the point of sale.
Quality and transparency matter
Another finding is particularly relevant to us as a producer.
Participants value consistent product quality, transparent information about ingredients and access through a safe, regulated framework.
These elements can appear technical when discussing cannabis regulation. In practice, however, they are fundamental to consumer protection.
A regulated market can set clear standards for cultivation and production. It can establish quality requirements, product testing, transparent declarations and traceability throughout the supply chain.
The illicit market cannot provide these safeguards to the same standard.
Pure Production’s role in SCRIPT
Pure Production produces the cannabis products used in the SCRIPT study.
Our responsibility is clear. We provide consistently produced, quality-controlled and transparently declared cannabis products for this regulated research environment.
For us, SCRIPT is about more than supplying products. The study helps generate knowledge about how responsible cannabis regulation can work in practice.
Switzerland’s pilot projects offer a unique opportunity to examine the entire system. This includes cultivation, product quality, distribution, professional guidance, consumer behaviour and public health outcomes.
From research to evidence-based policy
No single interim result can answer every question about future cannabis regulation.
That is precisely why studies such as SCRIPT matter.
They help policymakers, researchers, public health experts and industry move the discussion away from assumptions and towards measurable outcomes.
Switzerland is currently considering the future regulatory framework for cannabis. Evidence from its pilot projects can help identify what works, what needs improvement and which safeguards a functioning legal market requires.
The first SCRIPT findings are another important step in that process.
We are proud to contribute to this research and look forward to further results as the study progresses.
Read the official SCRIPT interim results
The Cities of Bern, Biel and Lucerne and the Universities of Bern and Lucerne have published the first interim findings from the SCRIPT study.
Read the official SCRIPT interim results
Pure Holding AG
Swiss Cannabis Science.
From Plants to People.